Acurx Pharmaceuticals Inc. continues to post positive data for its lead candidate ibezapolstat but that didn’t stop the stock from tumbling. The antibiotic outperformed vancomycin in a phase IIb study treating Clostridioides difficile infection (CDI). Vancomycin is a standard of care in the indication. Ibezapolstat eradicated fecal CDI at day 3 in 15 of 16 patients compared to vancomycin, which eradicated fecal CDI in 10 of 14 patients. Read More
Kyverna Therapeutics Inc. disclosed a filing to raise up to $100 million in an IPO, becoming the sixth firm to announce plans for a U.S. listing in the new year, offering tentative hope that the public markets might prove more welcoming to biopharma firms after a lackluster 2023. Read More
Kriya Therapeutics Inc.’s unveiling of its new gene therapy program for thyroid eye disease (TED), KRIYA-586, added yet another player to the burgeoning space, where a handful of developers have reached the phase III stage. Read More
The U.S. FDA’s Jan. 5 approval of Florida’s plan to import prescription drugs from Canada to take advantage of their lower price triggered ongoing communication between senior U.S. officials and Canada’s Ministry of Health over Canadian concerns about maintaining sufficient drug supplies. Read More
PDC*line Pharma SA has received €4.7 million (US$5.1 million) in public funding as part of a €12.5 million project to apply its allogeneic leukemia-derived dendritic cell line in the development of personalized vaccines for treating colorectal cancer. Read More
Taiwan’s Bora Pharmaceuticals Co. Ltd. is acquiring Upsher-Smith Laboratories Inc. from Sawai Group Holdings Co. Ltd. and Sumitomo Corp. of Americas for $210 million to boost its commercial presence in the U.S. Read More
New hires and promotions in the biopharma industry, including: Arvinas, Cullgen, Day One, Inhibikase, Neuvivo, Nextpoint, Plexium, Starlight, Vaxcyte. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Allakos, AM-Pharma, Anavex, Arcutis, Aviceda, Chipscreen Newway, Hope Medicines, Kairos, Sarepta. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: ERS, Invo, Lee’s, Medac, Naya, Stemsight, Urogen, Windtree. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aruna, Atsena, Carsgen, Drug Farm, Halozyme, Hemogenyx, Innocare, Merck, Neuraptive, Nrx, Precigen, Presage, Regeneron, Roche, Solid, Takeda, XNK. Read More
